Skip to main content

Purification and proteomic analysis of potent fibrinolytic enzymes extracted from Lumbricus rubellus



Lumbrokinase derived from earthworms, Lumbricus rubellus is known to have fibrinolytic enzymes that have potential as therapeutic drugs due to its ability to dissolve fibrin. The current study is aimed to purify the Lumbrokinase from L. rubellus and identify its protein component.


Water extract of local earthworm Lumbricus rubellus revealed several proteins. Therefore, to identify its protein component, purification through HiPrep DEAE fast flow and proteomic analysis were conducted prior to identifications. A combination of two-dimension gel electrophoresis (2DE) and electrospray ionization mass spectrometry analysis was used to identify the purified fractions.


The purified fractions contain five protein bands, namely F25-1, F25-2, F85-1, F85-2, and F85-3, which displayed strong fibrinogenolytic activity. F25 fractions showed fibrinogenolytic activity of 974.85 U/mg, while F85 fractions showed higher activity of 1,484.11 U/mg. Fractions F85-1, F85-2, and F85-3 showed molecular weights of 42.6 kDa, 27.03 kDa, and 14 kDa, respectively and were identified as Lumbrokinase iso-enzymes.


This preliminary study indicates that the F25 and F85 fractions are similar to published fibrinolytic protease-1 and lumbrokinase, respectively, in terms of their amino acid sequence.


Cardiovascular diseases (CVD) such as myocardial infarction, arrhythmias, and stroke are the leading cause of morbidity and mortality worldwide, with 17 million deaths every year. In the various types of CVDs, thrombosis is among the most commonly occurring diseases of modern life and could be responsible for increasing number of deaths [1]. Traditionally, the treatment of thrombosis relied either on the use of anti-platelet and anti-coagulating agents such as heparin and warfarin or on surgical treatment. Fibrinolytic enzymes are agents that dissolve fibrin clots and are considered to be potential candidates in the treatment of many CVDs as thrombolytic agents [2]. A variety of fibrinolytic enzymes are obtained from various sources, such as plants [3], animals [4], and microorganisms [5].

Earthworm fibrinolytic enzymes (EFE) have been widely reported as potential therapeutic agents. EFEs could be extracted from various species of earthworms, such as Lumbricus rubellus [6,7,8,9], Eisenia fetida [10,11,12], E. andrei [13], and Perionyx excavatus [14]. These enzymes have potential application as active pharmaceutical ingredients (APIs) for the treatment of severe diseases such as heart or cerebral infarction and prevention of thrombus formation in surgery. More importantly, EFEs demonstrate high-temperature stability, strong tolerance to organic solvent, broad pH range, and some of them could be absorbed as an intact form into the bloodstream through the intestinal epithelium [15]. All these superior properties make these enzymes attractive as oral thrombolytic agents [12].

EFE, which is commercially available, is known as lumbrokinase. Lumbrokinase has shown therapeutic promise for dissolving clots, lowering blood viscosity, and reducing platelet aggregation [16]. The Lumbrokinase is the main factor in the earthworm extract responsible for anti-tumor activity [17]. It has also been applied as an oral thrombolytic agent to prevent cardiac and cerebrovascular diseases due to its strong fibrinolysis [18]. In addition, an experiment conducted by Wei et al. 2009 [19] revealed that coelomic fluid from L. rubellus displayed improved sciatic nerve regeneration and functional recovery following injury.

A standardized extract of L. rubellus named DLBS1033 possesses fibrinogenolytic activity on α, β, and γ-chain of fibrinogen. It also demonstrated anti-platelet aggregation and prolonged blood clotting time, which later confirmed its antithrombotic property [20]. Extensive studies have been carried out on DLBS1033 crude extract [20,21,22,23] for commercial purposes. However, this crude extract contains various EFEs and other impurities, which may cause side effects or reduced efficacy. Therefore, further purification and identification are required as quality assurance. This study aimed to purify the fibrinogenolytic proteins present in DLBS1033 which was then designated as DLBS1033P, thereby increasing the specific activity. Further, the proteomic analysis was performed to identify the protein components.


Fresh earthworms (Lumbricus rubellus, three to four months old) were obtained from the local breeder in Indonesia. A polyethersulfone (PES) hollow fiber membrane (0.1 µm & 10 kDa cut off), Diethylaminoethyl (HiPrep DEAE), and low molecular weight calibration kit for Sodium Dodecyl Sulphate Poly-acrylamide Gel Electrophoresis (SDS PAGE) (14,400 Da to 97,000 Da) were purchased from GE Healthcare. Broad pH range IPG strips (pH 3–10, 7 cm) were purchased from Bio-Rad. Other chemicals used were analytical grade and mainly from Sigma-Aldrich and Merck.


Fractionation of proteins containing in the crude extract of earthworms (DLBS1033) was performed by ultrafiltration using membrane (cut off 10 kDa) continued by Ion-exchange chromatography. Protein analysis were conducted prior to identification to characterized its protein profile and activity. The study was conducted at Dexa Laboratories of Biomolecular Sciences (DLBS) and Proteomic International for identification.

Lumbrokinase extraction and purification

Pure active components of DLBS1033P were obtained from DLBS1033, the L. rubellus crude extract from West Java (Indonesia). The DLBS1033 was extracted using purified water, followed by continuous centrifugation (7780 Kubota, Japan) at 6,000xg for 15 min. The supernatant was then filtered using a microfiltration membrane of 0.1 μm (GE, Sweden) and concentrated using ultrafiltration membrane (cut off 10 kDa) (GE, Sweden). The concentrate was purified by Fast Performance Liquid Chromatography AKTA Purifier (GE Healthcare, Sweden) using ion-exchange chromatography, HiPrep DEAE (diethylaminoethyl) FF column (GE, Sweden). The column was equilibrated with a 20 mM phosphate buffer (pH 7.5). The adsorbed proteins were eluted with a stepwise gradient of 0.25 M NaCl (25, 55, and 85%) in the same buffer at a 5 mL/min flow rate. Each protein peak eluted from the 25 and 85% gradients exhibiting fibrinogenolytic activity was harvested for further analysis.

SDS PAGE and zymogram analysis

DLBS1033P proteins were loaded (10 µl) and separated by 14% SDS PAGE [24] at 100 V, 200 mA for 2 h. The protein bands were visualized by Coommassie Brilliant Blue R-250 and the apparent molecular mass of the proteins was calculated using low molecular weight (LMW) standard protein markers (GE Healthcare, UK). The fibrinogenolytic proteins (lumbrokinase) presence in DLBS1033P were detected by Fibrinogen zymography and were observed as a clear zone against the blue background. Bovine fibrinogen at a final concentration of 0.5% was used as a substrate.

Protease activity and protein content

Protease activity was determined according to standardized Sigma procedure. The reaction mixture containing 250 μL of (25 mg/mL) DLBS1033P in 20 mM potassium phosphate buffer and 1.25 mL of 0.65% (w/v) bovine fibrinogen (Sigma, USA) was incubated at 37 °C for 10 min. The reaction was terminated by 250 µL of 110 mM Trichloroacetic acid solution (Merck, Germany). A blank was prepared by adding TCA sample, followed by the addition of the substrate. After vortexing for 5 s, the soluble peptides were separated by centrifugation at 9200xg for 10 min. Half the volume of supernatant was mixed with 1.25 mL sodium carbonate (Sigma, USA), and 0.25 mL Folin’s reagent was added under basic conditions by addition of Na2CO3 solution (Merck, Germany). Absorbance was measured using Agilent Spectrophotometer Cary 60 Ultraviolet/Visible (UV/Vis) at 660 nm. One unit is defined as the amount of enzyme that hydrolyzes fibrinogen to produce absorbance equivalent to 0.5 nmol tyrosine per minute at pH 7.5 at the temperature of 37 ºC. The protein concentration was measured according to Lowry method [25].

Two-dimension gel electrophoresis

DLBS1033P proteins were separated by Two-Dimension Gel Electrophoresis (2DE) using a wide range of immobilized pH gradient (IPG) strip (pH 3–10) in the first dimension and 14% SDS-PAGE in the second dimension. The DLBS1033P (equal to 200 µg protein) was diluted using rehydration buffer (urea 8 M, CHAPS 2%, Dithiothreitol 50 mM, Bio-lyte 0.2% and bromcresol blue). IPG strip was treated with rehydrated solution under passive condition for 16 h at a temperature of 4 °C. Proteins were visualized by Coomassie Brilliant Blue R-250 staining. A 2D zymography was performed using native polyacrylamide gel containing 0.5% bovine fibrinogen.

Fibrinolytic activity

The fibrinolytic activity of lumbrokinase fractions was measured using fibrin plate assay. As much as 7.3 ml of 0.5% agarose was poured onto the sterile petri dish, followed by slow addition of 200 μL of 1 mg/ml thrombin and 2.5 mL of 1% fibrinogen. The solution was solidified for 1 h at 37 °C. Membrane discs (diameter of 0.6 cm) were placed on the fibrin surface. Lumbrokinase fractions at equal concentration were placed onto the disc and incubated at 37 °C for 18 h. The diameter of the hydrolyzed clear zone was measured and calculated as fibrinolytic activity of the samples.

Protein identification

Each protein spot was manually excised from the 2DE gel. Each sample was trypsin digested and the peptides were extracted following standard technique prior to mass spectrometry (MS) analysis [26]. Each peptide ion data that was fragmented within the MS was matched to the possible amino acid sequences in the database. The resulting sequences were searched against the National Center for Biotechnology Information (NCBI) protein database using basic local alignment search tool (BLAST) to provide the sequence coverage of DLBS1033P’s peptides in each spot to the predicted protein. Blast analysis was subsequently conducted and followed by sequence alignment ( All procedures performed in this study were conducted at Proteomics International (PI, Broadway, Nedlands Australia).


Enzyme purification from DLBS1033

DLBS1033, the proteins extracted from Lumbricus rubellus, comprises complex fibrinolytic enzymes as reported earlier [20]. Water extract of the earthworms contains 20.259 mg/g of protein with fibrinolytic activity of 113.79 U/mg. Based on the zymogram & SDS-PAGE analysis, it was confirmed that DLBS1033 contained 7 fibrinogenolytic enzymes with molecular weight ranging from 14 to 66 kDa. The active components from the crude enzyme purified using HiPrep DEAE (diethylaminoethyl) FF 16/10 column (Fig. 1) displayed two fibrinogenolytic bands with molecular weight > 45 kDa (F25, Fig. 2a), which were eluted with lower ionic strength buffer (25% of NaCl 0.25 M in Phosphate buffer). Three fibrinogenolytic enzymes < 45 kDa (F85, Fig. 2a) were obtained from elution using higher ionic strength buffer (85% of NaCl 0.25 M in Phosphate buffer). Due to lower fibrinolytic activity, the fractions eluted with intermediate ionic strength buffer (55% and 70%) were not analyzed further. The 85% fraction containing enzymes with molecular weight of 42.66 (F85-1), 27.03 (F85-2), and 14 kDa (F85-3) was selected based on its higher fibrinolytic activity. The purification result is summarized in Table 1.

Fig. 1
figure 1

Chromatogram of ion exchange chromatography

Fig. 2
figure 2

DLBS1033P Protein Profile. Zymogram (a) and SDS-PAGE gel (b) profiles of purified enzymes in DLBS1033. Crude: crude extract of DLBS1033 (135.1 µg protein); F25: DEAE FF purification (F25 fraction, 3.2 µg protein); F85: DEAE FF purification (F85 fraction, 74.4 µg protein)

Table 1 The activity of DLBS1033 during multi-step purification

Two-dimension gel electrophoresis

A 2D electrophoresis was conducted with purified enzymes from DLBS1033 prior to identification. At the first dimension, DLBS1033P was separated by IEF based on its pI. IPG strip 3–10 was selected due to its broad-range pH gradients for maximum protein resolution. Figure 3 depicts the visualization of the 2DE protein profiles of DLBS1033P (F25 & F85). More F25 fraction spots (spot P2, P5, P7, P8, P9) were shown at pI 4.0 with various molecular weights. Several spots suspected as fibrinolytic proteases (based on their molecular weights) were selected (Fig. 3a). Furthermore, the 2DE revealed that each F85-1 and F85-2 fraction was separated into 2 proteins (Fig. 3b, spot D1 and D4, for F85-1 and D2 and D4 for F85-2). While, protein F85-3 showed only one spot (Fig. 3b, spot D5) with poor spot separation at the bottom of the running gel. Two spots of similar molecular weight but with opposites pIs (pI 3.5 and pI 10) showed fibrinolytic activity on 2D zymogram (Fig. 3c). Each spot (Fig. 3b, D1, D2, D3, D4, and D5) was excised and used for protein identification using MS analysis.

Fig. 3
figure 3

2D Electrophoregram of DLBS1033P fractions. F25 fraction (a) F85 fraction (b) 2D zymogram of F85 fraction (c)

Fibrinolytic activity

Fibrinolytic activity of DLBS1033 crude and DLBS1033P were also measured using fibrin plate assay. Preparation for fibrin degrading activity using fibrin plate was also conducted such that the protein amount of each samples tested were within 1.2 – 1.6 µgram. The diameter of clear zone was measured and the volume of lysis caused by the enzyme were calculated. Figure 4 (a-d) showed fibrinolytic activity after 18 h incubation at 37 °C. At similar protein amount the purified fractions (Fig. 4b and c) exhibited higher diameter of the clear zone on the fibrin plate compare to DLBS1033 crude indicating their fibrin degradation activities were better than the crude DLBS1033. The increase in diameter of the resulting clear zone were also observed every 2 h on each samples (Fig. 4e).

Fig. 4
figure 4

Fibrinolytic activity. DLBS1033 crude (a) DLBS1033P F85 fraction (b) DLBS1033P F25 fraction (c) negative control (d) volume of fibrin clot lysis observation (e)

DLBS1033P Identification

The peptide sequence of protein spots of F25 fractions (P2, P5, P7, P8, and P9) and F85 fractions (D1, D2, D3, D4, and D5) was analyzed, resulting in 100% identity of spots P5, P8, and P9 to fibrinolytic protease-1 (Table 2). P2 and P7 spots showed protein hit as annexin and partial amino acid sequence of lumbrokinase, respectively (Table 2). Moreover, the peptide sequence of some spots obtained from F85 fractions was also analyzed. Spots D1 and D4 with similar molecular weight but different pI values were predicted as lumbrokinase (Table 2). Spot D2 and D3 showed partial sequence of lumbrokinase with 100% identity. Spot D5, which showed poor separation, showed 88% identity to lumbrokinase (Table 2).

Table 2 Peptide information of F25 and F85 fraction generated from MS spectra

Furthermore, for protein identification, amino acid sequences of peptides obtained from each spot were overlapped to those of protein hit. The percentage of sequence coverage from all matched peptides to the mature peptide of the predicted protein was also calculated. The sequence alignments analysis of the F25 fraction (Table 3) showed that the highest similarity was obtained from the spot P9, which was identified as fibrinolytic protease-1, and P7 as partial lumbrokinase with % coverage of 28.93% and 19.14, respectively. Meanwhile, the F85 fraction (Table 3) showed D1 and D4 shared considerable similarity as lumbrokinase with coverage of 24.81%. Spot D2 and D3 appeared as partial lumbrokinase from E. fetida or L. rubellus, with coverage of 20.25%.

Table 3 Amino acid sequence alignment of DLBS1033P—F25 and F85 spots


The number of research aiming to find basic scientific background on the utilization of medicine and traditionally used herbs that include animal products such as earthworms are growing. DLBS1033 generated from local Indonesian earthworms has been the focus of our work. In this experiment, we studied DLBS1033P, a purified form of DLBS1033, consisting of fibrinolytic iso-enzymes with molecular weight ranging from 27 to 45 kDa. This range was wider than the fibrin degrading enzymes reported by Phan et al. 2011 which was (27.5–34.5) kDa[27]. Both F25 & F85 fractions of DLBS1033P shared proteins with the same isoelectric points (pI) value of 3.5, similar to fibrinolytic enzymes reported by Wang et al. 2003 with pI values of 3.46–3.94 [28], and slightly different from that reported by Phan et al. 2011 (4.3–5.2) [27]. The differences in protein charges between DLBS1033P and other reports mentioned above might be partly related to the different methods of preparation and purification of crude powder of earthworms fibrinogenolytic enzymes. Cultivation methods of the local earthworms, such as feed material and pH of culture medium, may also affect the characteristics of the protein synthesized within the earthworm as well as in genetic and protein expression between earthworms.

The purification of fibrinogenolytic enzymes of DLBS1033 resulted in two fractions F25 and F85, and both showed higher fibrinolytic activities compared to DLBS1033 which also been reported to have fibrinolytic acitivity by Trisina et al. 2011 [20]. EFEs analysis identified F25 fractions as Fibrinolytic protease-1 and F85 fractions as lumbrokinase and partial lumbrokinase with % coverage above 20%. The % coverage (i.e., the proportion of a theoretical protein that is covered by MS data of a protein spot) can be used as a parameter for protein identification [29]. According to many proteomics researchers, more than 20% of coverage is likely to be significant [30, 31]. Fibrinolytic protease-1 was identified on the P9 of 45 kDa protein with relatively high % coverage i.e. 28.93%. The result correlated well with the zymogram profile (Fig. 2), which also showed that fibrinogenolytic protein bands were detected at around 45 kDa. Unlike F25 fractions, all proteins identified in the F85 fractions were EFEs. F85-1 contained 2 isoform spots (D1 and D4) identified as lumbrokinase (24.81% coverage), which shared the same molecular weight of 42.6 kDa but with different pI values (3.5 and 10). F85-2 with molecular weight of 27.03 kDa was likely to be part of lumbrokinase protein and was identified as lumbrokinase partial (20.25% coverage). Lower % coverage was shown on P2, P5, P7, and P8 spots (Table 3). Low sequence coverage can be caused by insufficient number of samples, wide dynamic range of protein concentration in a complex mixture, and a wide range of electrospray ionization efficiency [32]. Salzano et al. 2005 reported that only 2 or 3 matched peptides are required to identify protein confidently [33]. Other protein such as annexin, identified as 68 kDa (P2 spot), is not related to fibrinolytic protein. Annexin is a Ca2+ -regulated phospholipid-binding protein plays a vital role in the cell life cycle, exocytosis, and apoptosis [34].

Two proteins were identified in DLBS1033P: fibrinolytic protease-1 and lumbrokinase, which are known to be EFEs supporting the activity of DLBS1033 as an antithrombotic agent. Currently, EFEs products in the market are crude earthworms protein without fractionation and containing many other proteins or impurities. DLBS1033 has been clinically tested and concluded that at the dose of 490 mg 3 times daily was safe in healthy adults [35] and provided a safe hemostasis profile in ischemic stroke patients [36]. The F85 fraction of DLBS1033P, which only contains EFEs protein, is suggested to have better safety and pharmacological effects compared to DLBS1033. This is due to a higher fibrinolytic activity and specific activity of 13-fold over crude DLBS1033. The limitation of this research was in purifying L. rubellus species from other earthworms species in raw materials from local suppliers in large quantities. Therefore, small amount of other species besides L. rubellus might still be present in the extract.


Proteomic analysis of DLBS1033P revealed that most of the protein components in DLBS1033 were earthworm fibrinolytic enzymes (EFE), which were identified as 45 kDa fibrinolytic protease-1 with percent coverage of 28.93% and 42.6 kDa and 27.03 kDa lumbrokinases with sequence coverage of 24.81 and 20.25%, respectively. The purification process to separate EFEs protein from other proteins resulted in F85 fractions with increased specific activity up to 13-fold.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.





Two-dimension gel electrophoresis


Cardiovascular diseases


Earthworm fibrinolytic enzymes


Active pharmaceutical ingredients




Low molecular weight


Sodium dodecyl sulfate–polyacrylamide gel electrophoresis


Mass spectrometry


Isoelectric points


  1. Yuan J, Yang J, Zhuang Z, Yang Y, Lin L, Wang S. Thrombolytic effects of Douchi Fibrinolytic enzyme from Bacillus subtilis LD-8547 in vitro and in vivo. BMC Biotechnol. 2012;2012(12):36.

    Article  Google Scholar 

  2. Taneja K, Bajaj BK, Kumar S, Dilbaghi N. Production, purification and characterization of fibrinolytic enzyme from Serratia sp. KG-2-1 using optimized media. 3 Biotech. 2017;7(3):184.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Chung DM, Choi NS, Chun HK, Maeng PJ, Park SB, Kim SH. A new fibrinolytic enzyme (55 kDa) from Allium tuberosum: purification, characterization, and comparison. J Med Food. 2010;13:1532–6.

    Article  CAS  PubMed  Google Scholar 

  4. Huang MX, Ye Y, Chen YX, Han YL. Partial purification and characterization of fibrinolytic enzymes from yellow mealworm. Int J Pept Res Ther. 2012;18:153–61.

    Article  CAS  Google Scholar 

  5. Ju X, Cao X, Sun Y, Wang Z, Cao C, Liu J, Jiang J. Purification and characterization of a fibrinolytic enzyme from Streptomyces sp. XZNUM 00004. World J Microbiol Biotechnol. 2012;28:2479–86.

    Article  CAS  PubMed  Google Scholar 

  6. Dharmawati IGAA, Mahadewa TGB, Widyadharma IPE. Antibacterial activity of Lumbricus rubellus earthworm extract against Porphyromonas gingivalis as the bacterial cause of periodontis. Maced J Med Sci. 2019;7(6):1032–6.

    Article  Google Scholar 

  7. Wang YH, Chen KM, Chiu PS, Lai SC, Su HH, Jan MS, Lin CW, Lu DY, Fu YT, Liao JM, Chang JT, Huang SS. Lumbrokinase attenuates myocardial ischemia-reperfusion injury by inhibiting TLR4 signaling. J Mol Cell Cardiol. 2016;99:113–22.

    Article  CAS  PubMed  Google Scholar 

  8. Samatra DPGP, Tjokorda GBM, Sukrama DMI, Dewi NYS, Praja RK, Nurmansyah D. Widyadharma IPE. Extract of earthworms (Lumbricus rubellus) reduced malondialdehyde and 8-hydroxy-deoxyguanosine level in male Wistar rats infected by Salmonella typhi. Biomed Pharmacol J. 2017;10(4):1765–71.

    Article  Google Scholar 

  9. Permana S, Hadi RP, Norahmawati E, Endharti AT. Coelomic fluid of Lumbricus rubellus enhances anti-prolioniferative effect of 5-fluorouracil by modulating focal adhesion kinase express and IL-1β of colorectal cancer in mice. J Appl Pharm Sci. 2019;9(08):041–6.

    Article  CAS  Google Scholar 

  10. Ozkan AD, Eskiler GG, Sarihan M, Kazan N, Aksoy O, Yuksel B, Betts Z. Anticancer properties of Eisenia foetida proteins in prostate cancer cells in vitro. Int J Pept Res Ther. 2022;28:119.

    Article  CAS  Google Scholar 

  11. Liu CM, Chen XT, Pan YY, Liang H, Song SL, Ji AG. Antitumor studies of earthworms fibrinolytic enzyme component A from Eisenia foetida on breast cancer cell line MCF-7. Indian J Pharm Sci. 2017;79(3):361–8.

    Article  CAS  Google Scholar 

  12. Lannuci NB, Camperi SA, Cascone O. Purification of enzymes from earthworms. Dynam Soil Dynam Plant. 2009;3(Special issue 2):64–8.

  13. Lee CK, Shin JS, Kim BS, Cho IH, Kim YS, Lee EB. Antithrombotic effects by oral administration ofnovel proteinase from earthworm Eisenia andrei on venous thrombosis model in rats. Archives Pharmacal Res. 2007;30:475–80.

    Article  CAS  Google Scholar 

  14. Thuy LTB, Tuyen ET, Dao NTN. Purification and identification of some characters of the fibrinolytic enzyme isolated from the earthworm Perionyx excavatus. Biology Magazine (Vietnam). 2006;2006(28):77–82.

    Google Scholar 

  15. Fan Q, Wu C, Li L, et al. Some features of intestinal absorption of intact fibrinolytic enzyme III-1 from Lumbricus rubellus. Biochim Biophys Acta. 2001;1526(3):286–92.

    Article  CAS  PubMed  Google Scholar 

  16. Cooper EL, Ru B, Weng N. Earthworms: sources of antimicrobial and anticancer molecules. Adv in Experiment Med Biol. 2004;546:359–89.

    Article  Google Scholar 

  17. Chen H, Takahasi S, Imamura M. Earthworm fibrinolytic enzyme: anti-tumor activity on human hepatoma cells in vitro and in vivo. Chin Med J. 2007;120:898–904.

    Article  CAS  PubMed  Google Scholar 

  18. Verma MK, Pulicherla KK. Enzyme promiscuity in earthworm serine protease: substrate versatility and therapeutic potential. Amino acid. 2016;48:941–8.

    Article  CAS  Google Scholar 

  19. Wei S, Yin X, Kou Y, Jiang B. Lumbricus extract promotes the regeneration of injured peripheral nerve in rats. J Ethnopharm. 2009;123:51–4.

    Article  Google Scholar 

  20. Trisina J, Sunardi F, Suhartono MT, Raymond R, Tjandrawinata RR. DLBS1033, a protein extract from Lumbricus rubellus, possesses antithrombotic and thrombolytic activities. J Biomed Biotechnol. 2011;2011:1–8.

    Article  Google Scholar 

  21. Tjandrawinata RR, Trisina J, Rahayu P, Prasetya LA, Hanafiah A, Rachmawaty H. Bioactive protein fraction DLBS1033 containing lumbrokinase isolated from Lumbricuss rubellus: ex vivo, in vivo, and pharmaceutic studies. Drug Des Dev Ther. 2014;8:1585–93.

    Article  Google Scholar 

  22. Gayatri A, Nafrialdi N, Setiabudy RD, Tjandrawinata RR, Rachman A, Louisa M. A Clinical trial on biological half life of bioactive protein from Lumbricus rubellus, DLBS1033 in healthy volunteers. Indones J Intern Med. 2018;50(3):208–14.

    Google Scholar 

  23. Christy G, Tjandrawinata RR, Rachmawati H. Tabletting process of pellets containing bioactive fraction DLBS1033F isolated from Lumbricus rubellus: challenge and strategy. Bio Pharm Bull. 2015;38(12):1843–9.

    Article  CAS  Google Scholar 

  24. Laemmli UK. Cleavage of structural protein during the assembly of the head of bacteriophage T4. Nature. 1970;227:680–5.

    Article  CAS  PubMed  Google Scholar 

  25. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin-Phenol reagents. J Biol Chem. 1951;193:265–75.

    Article  CAS  PubMed  Google Scholar 

  26. Bringans S, Eriksen S, Kendrick T, Gopalakrishnakone P, Livk A, Lock R. Proteomic analyses of the venom of Heterometruslongimanus (Asian black scorpion). Proteomics. 2008;8:1081–96.

    Article  CAS  PubMed  Google Scholar 

  27. Phan TT, Ta TD, Nguyen DT, Van Den Broek LA, Duong GT. Purification and characterization of novel fibrinolytic proteases as potential antithrombotic agents from earthworm Perionyx excavatus. AMB Express. 2011;1(1):26.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Wang F, Wang G, Li M, Cui L, Zhan J, Chang W. Purification, characterization and crystallization of a group of earthworm fibrinolytic enzymes from Eisenia foetida. Biotechnol Lett. 2003;25:1105–9.

    Article  CAS  PubMed  Google Scholar 

  29. Biron DG, Brun C, Lefevre T, Lebarbenchon C, Loxdale HD, Chevenet F, Brizard JP, Thomas F. The pitfalls of proteomics experiments without the correct use of bioinformatics tools. Proteomics. 2006;6:5577–96.

    Article  CAS  PubMed  Google Scholar 

  30. Damodaran S, Wood TD, Nagarajan P, Rabin R. Evaluating peptide mass fingerprinting-based protein identification. Geno Prot Bioinfo. 2007;5:3–4.

    Article  Google Scholar 

  31. Barret J, Brophy PM, Hamilton JV. Analysing proteomic data. Int J Parasitol. 2005;35(5):543–53.

    Article  Google Scholar 

  32. Garza S, Moini M. Analysis of complex protein mixtures with improved sequence coverage using (CE-MS/MS). Anal Chem. 2006;78(20):7309–16.

    Article  CAS  PubMed  Google Scholar 

  33. Salzano AM, Crescenzi M. Mass spectrometry to protein identification and the study of post translational modifications. Ann Ist super Sanita. 2005;41(4):443–50.

    PubMed  Google Scholar 

  34. Mirsaeidi M, Gidfar S, Schraufnagel D. Annexins family: insights into their functions and potential role in pathogenesis of sarcoidosis. J Transl Med. 2016;14:89.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Tjandrawinata RR, Yunaidi DA, Susanto LW. The safety and tolerability of lumbrokinase DLBS1033 in healthy adult subjects. Drug Res. 2016;66(6):293–9.

    Article  CAS  Google Scholar 

  36. Setyopranoto I, Wibowo S, Tjandrawinata RR. Hemostasis profile and clinical outcome of acute ischemic stroke patients treated with oral lumbrokinase DLBS1033: a comparative study versus aspirin and clopidogrel. Asian J Pharm Clin Res. 2016;9(1):171–7.

    Google Scholar 

Download references


The authors would like to thank Theresia Monica Ginting and Destrina Grace Simanjuntak for proofreading the manuscript.


This project is under Dexa Medica concern and support, including the publication fee.

Author information

Authors and Affiliations



LS conducted all the experiments and analysis as well as wrote the manuscript. PR supervised the experiments, reviewed the data analysis and the manuscript. DR, MTS, HR, and RRT reviewed the manuscript. The author(s) read and approved the final manuscript.

Corresponding author

Correspondence to Raymond R. Tjandrawinata.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Stephani, L., Rahayu, P., Retnoningrum, D. et al. Purification and proteomic analysis of potent fibrinolytic enzymes extracted from Lumbricus rubellus. Proteome Sci 21, 8 (2023).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: